B-OM has been given the go-ahead by the FDA to proceed to phase 3 so it did show sufficient efficacy in phase 2 to do so. We simply don't have the funding to do so at this time.
Prurisol is in no way related to Brilacidin so the word "siblings" should not be used to link Prurisol's failure with Brilacidin's chances in any way.
B-ABSSSI has nothing to do with Italy or Italians. You must be thinking of Kevetrin which the Italians are doing work on.
With the recent engagement with Locust Walk to get some deals done, you might want to brush up on your pipeline DD so you can make better decisions regarding IPIX. Very exciting times coming up for the company. There is serious potential upside from here.
News 
Market Data 
Discover 
